Ranjit Nair, MD
Pulmonary Disease · N.richland Hills, TXNPI 1407055221
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Boehringer Ingelheim at 27.4% of the total. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 924 payments — averaging $143.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$36K
- Mylan Specialty L.p.$30K
- AstraZeneca$16K
- Jazz Pharmaceuticals Inc.$11K
- Intuitive Surgical$11K
- Viatris Specialty LLC$7K
- plus $22K from 54 others
Across 55 payments — averaging $18,782 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$720K
- Amgen$246K
- Sanofi US Services Inc.$33K
- Regeneron$19K
- Jazz Pharmaceuticals Inc.$8K
- Pfizer$7K
What the payments were for
- Consulting fees$21,90417%
- Speaking & faculty fees$70,35153%
- Travel & lodging$7,6126%
- Food & beverage$22,96317%
- Education$9,2607%
- Gifts$6010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$35,785
- TEZSPIRE$12,696
- XYWAV$9,911
- OFEV$6,943
- ION$6,000
- Da Vinci Surgical System$4,463
- TAGRISSO$1,395
- Inspire$988
- BREZTRI$973
- DUPIXENT$971
- XYREM$915
- AIRSUPRA$766
- FASENRA$583
- TRELEGY ELLIPTA$358
- remede System$303
- SAPIEN 3 Ultra RESILIA$286
- SMARTVEST$282
- Arikayce$272
- Wakix$268
- Monarch Platform$208
How this compares
$132,691 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 86 | $1,114,786 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 425 | $452,954 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 365 | $361,396 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 31 | $250,236 |
| Dupixent PenDupilumab | 37 | $160,420 |
| TezspireTezepelumab-Ekko | 33 | $153,808 |
| Pirfenidone | 32 | $95,787 |
| Spiriva RespimatTiotropium Bromide | 76 | $56,995 |
| Breo ElliptaFluticasone/Vilanterol | 83 | $54,026 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $44,004 |
| SymbicortBudesonide/Formoterol Fumarate | 84 | $33,723 |
| Incruse ElliptaUmeclidinium Bromide | 50 | $26,638 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $15,457 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $15,134 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 95 | $13,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $36,296 | $1,202,372207 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,042 | $585,271638 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $15,525 | $548,927482 claims |
| Grifols USA, LLCProlastin C | $410 | $250,23631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in N.richland Hills
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.